Malignant Nodular Hidradenoma: Isolated Case Report and Review of Literature

SA KHAN a, AAA ALI b, S FERDOUSI c, M RIYAD d, AAH MAHMUD e

Summary:

Malignant Nodular Hidradenoma is an infrequent highly malignant, primary skin tumor derived from eccrine sweat glands. It has an aggressive course, with high recurrence, high rate of metastases and has very poor prognosis. It has been described as an “orphan” neoplasm. The tumor is similar to its benign counterpart but had additional features such as surface ulceration, numerous mitotic figures and infiltrative growth pattern. Pre-operative diagnosis is difficult by the fine needle aspiration cytology. Malignant nodular hidradenoma of chest wall in 35 years old women, who presented to us with a recurrent rapidly growing swelling over chest wall that grew rapidly over two months after first excision. Tissue diagnosis of first excised specimen was eccrine poroma that was similar to its benign counterpart.

Key words: sweat gland tumor, malignant hidradenoma, eccrine poroma, spiradenoma.

Introduction:

Malignant tumors of the sweat glands represent rare oncological entities, characterized by non-specific clinical presentation and equivocal pathological features. Their precise diagnosis and histological classification can be very difficult. It is an extremely rare tumor with less than 50 cases reported1.

Hidradenomas arise as intradermal nodules from eccrine sweat glands. Ultrastructural and enzyme histochemical studies have shown nodular hidradenomas to be intermediate between eccrine poroma and eccrine spiradenoma2. The histology of the malignant hidradenoma resembles of it’s benign counterpart. The criteria for malignancy include poor circumscription, presence of nuclear atypia, mitotic activity, presence of predominantly solid cell islands, infiltrative growth pattern, necrosis, and angio-lymphatic permeation3-5.

We report a case of malignant nodular hidradenoma in a middle aged woman who presented with a recurrent swelling in right side of lower chest wall.

Case report:

A 35 years old female presented to us with swelling over right side of chest wall. The swelling was excised and sent for histopathology. The report was eccrine poroma. But it recurred after two months. The swelling was rapidly increasing in size over the last one and half months. The mass became significantly prominent over the last 15 days prior to presentation resulting in discomfort.

Physical examination revealed a large lobulated mass about 20 cmx15cm in size, without ulceration. It was hard, non-mobile, non-fluctuant and adherent to the old scar. The draining area showed no palpable lymphnode. General examination including lungs and liver were normal. Per-operatively, a hard fibrous tumor was observed to infiltrate the muscle but not to underlying ribs. Wide local excision with 1 cm marginal clearance of healthy surrounding tissue was performed along with primary closure. Biopsy was sent to pathological examination.
Pathological findings:
GROSS: Partly skin covered with grayish yellow mass measuring 18x11x7cm. Skin surface shows a part of old incision mark measuring 5.5 cm in length. The cut surface shows a grey brown lobulated tumor with area of cystic change.

Microscopic description: The dermis presents a malignant tumor with infiltrating border made of polygonal cells showing mild to moderate pleomorphism. Mitotic figures are frequent. Areas of necrosis are seen. The deep resection margin and peripheral resection margins are free from tumor. The tumor exhibited infiltrative growth pattern. A diagnosis of malignant nodular hidradenoma was made.

Discussion:
The recognition of hidradenoma as a distinct entity was first reported in 1941 by Mayer, whereas the term “clear cell hidradenoma” was proposed in 1954 by Keasby and Hadley. The malignant form of hidradenoma is extremely rare, with less than 50 cases ever reported in the literature. All these cases were characterized by a significant rate of locoregional recurrence. Some patients developed distant metastatic spread as well.

The disease is usually expressed as a small intradermal mass which remains inactive for a long period of time before increasing in size. Its aggressive behavior is more apparent after each local relapse with faster growth and invasion of the surrounding tissues. In most cases, no epidermal participation is encountered. Hidradenoma usually affects middle-aged women, although its malignant form shows no age or gender predilection.

Malignant hidradenoma is usually found in the scalp, face or anterior surface of the trunk. These lesions tend to metastasized and may cause death.

Although there is insufficient evidence in the literature, the recurrence rate may be estimated at about 50% and metastasis rate is about 60% including metastasis to regional nodes, bone, viscera and skin.

Histologically, clear cell hidradenoma seems to originate from the ductal epithelium of the sweat glands, whereas histogenetically it appears to represent a transitional tumor, sharing features of eccrine poroma and eccrine spiradenoma.

Malignant nodular hidradenoma are usually larger, asymmetrical, and show invasion into surrounding tissue.
tissue. In addition, there may be angio-lymphatic invasion. Mitosis are usually easily detected, and some may be atypical. Tumor necrosis, areas of high cellularity, and focal and diffuse areas of marked cytological atypia in which differentiated elements are unrecognizable are present in some examples. In some cases of Malignant nodular hidradenomas, nuclear anaplasia may be only slight to moderate or even absent in the both primary tumors and the metastasis. Nuclear anaplasia, if present, may be limited to the clear cells or affect both the polyhedral and clear cells.

The recognition of the eccrine origin of a malignant hidradenoma may be accomplished through specific immunohistochemical techniques, a positive PAS stain, as well as with the presence of lobules with epidermal differentiation. Sweat glands neoplasms generally arise from the eccrine cellular lineage, they exhibit cellular growth patterns that may further influence the neoplasm’s architecture. Hidradenoma may exhibit both cystic and solid features and that is why it enters on differential diagnosis with apocrine tumors; in fact there are divergent opinions on the primitive cellular lineage. The issue is complicated by the coexistence of eccrine and apocrine cells inside cutaneous hamartomas or inside adnexal tumors with mixed differentiation (follicular and sebaceous).

Malignant clear cell hidradenoma usually develops de novo and invades the dermis and subcutaneous tissue. Surprisingly, it might share significant histopathological features with its benign form. The mitotic index may not be representative or may affect only a small cellular subpopulation. Thereafter, the diagnosis of malignancy through standard pathological examination may prove extremely difficult.

In our case, it was interesting to note that, in contrast to the final diagnosis, previous pathology reports had ascertained the presence of an eccrine poroma. The latter is a benign tumor of the sweat glands with similar clinical presentation and equivocal enzyme reactions, which pose tremendous diagnostic dilemmas. Because of the rarity of these oncological entities, as well as their histopathological similarity, it is almost impossible to define whether a malignant clear cell hidradenoma had been developed from a benign eccrine poroma or was the correct diagnosis from the beginning.

The most recent reports support the fact that malignant clear cell hidradenoma should be considered as a distinct entity rather than the result of a malignant transformation of its benign type, underlining the importance of a precise initial diagnosis. Rosen et al. presented a case of a clear cell hidradenoma of the eyelid complicated by multiple recurrences and invasion of nearby structures. Histologically, no atypia or increased nuclear mitoses were found. The precise identification of a benign or malignant hidradenoma, based on pathological examination, was not possible. Similar findings were noted in other case reports of clear cell hidradenoma.

Surgical excision remains the therapeutic modality of choice. Wong et al. supported wide surgical resection with a least 2 cm of clear margins for both primary disease and local recurrences. Elective regional lymphadenectomy after lymphoscintigraphy should also be performed. The role of sentinel lymph node biopsy in the treatment of malignant hidradenoma is controversial. Locoregional recurrence even after wide surgical excision has been reported in more than 50% of cases, although overall and disease-free survival rates are hard to determine as the result of the very limited number of reported cases. Adjuvant chemotherapy and radiotherapy have no impact in local control or survival.

The use of Mohs micrographic surgery with superior evaluation of surgical margins has been utilized more recently as the primary treatment modality. The use of sentinel lymph node biopsy also has been reported to be useful, especially given the propensity for the metastatic spread.

Immunohistochemistry revealed strong positivity for Epithelial Membrane Antigen (EMA), Estrogen and Progesterone Receptors (EPR) and CEA. P63, CFDP-15 and C-erbB2 were negative. Ki67 decorated 40% of neoplastic cells, which has been sparked interest in treatment with hormone therapy. Schröder et al. reported the use of tamoxifen as adjuvant therapy for an estrogen receptor positive metastatic sweat gland adenocarcinoma. Further study has also been going on.

**Conclusion:**

Malignant clear cell hidradenoma is a rare oncological entity, with no particular clinical or histopathological features. It should be included in the differential
diagnosis of dermal lesions with an aggressive behavior and multiple recurrences, despite aggressive surgical treatment.

References:


